[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622563":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":30,"collaborators":25,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":25,"eligibilityCriteria":38,"healthyVolunteers":39,"sex":40,"minAge":41,"maxAge":25,"enrollmentInfo":42,"targetDuration":25,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":25,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":25},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Single-dose oral administration of AD-2291 (Rebamipide 100mg) in Period 1, followed by single-dose oral administration of AD-229 (Rebamipide 300mg) in Period 2.",[13,14],"Drug: AD-229","Drug: AD-2291",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B","Single-dose oral administration of AD-229 (Rebamipide 300mg) in Period 1, followed by single-dose oral administration of AD-2291 (Rebamipide 100mg) in Period 2.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-229","AD-229 Oral Tablet",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AD-2291","AD-2291 Oral Tablet",[9,16],{"type":31,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100622563","phase-1-a-clinical-trial-to-assess-the-pharmacokinetics-and-safety-of-ad-229-compared-to-ad-2291-in-healthy-adults-100622563",false,"NCT07385248","A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults","An Open-label, Randomized, 2-treatment, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-229 and the Administration of AD-2291 for Healthy Adults in Fasting State","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years",{"count":43,"type":44},28,"ESTIMATED","INTERVENTIONAL",[47],"PHASE1","The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.",[50],"Gastritis","NOT_YET_RECRUITING","2026-02-26",{"date":54,"type":55},"2026-02-27","ACTUAL",{"date":57,"type":44},"2026-04",{"date":59,"type":44},"2026-06",{"name":5,"class":6}]